Product Description: Tat-NR2B9c TFA (Tat-NR2Bct TFA) is a postsynaptic density-95 (PSD-95) inhibitor, with EC50 values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c TFA disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC50 values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c TFA also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy[1].
Applications: Neuroscience-Neurodegeneration
Formula: C105H188N42O30.C2HF3O2
Citations: Behav Brain Res. 7 January 2022, 113537./Biochem Biophys Res Commun. 2024 May 8:720:150076./J Cereb Blood Flow Metab. 2019 Aug;39(8):1588-1601. /J Neuropathol Exp Neurol. 2020 Jul 1;79(7):800-808./Neuropharmacology. 2024 Mar 21:109905./Neuroreport. 2021 Sep 8;32(13):1122-1127./PLoS One. 2020 Mar 3;15(3):e0229499. /Sci Rep. 2018 May 18;8(1):7848.
References: [2]Fan J, et al. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease. Neurobiol Dis. 2012 Mar;45(3):999-1009./[1]Cui H, et al. PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors. J Neurosci. 2007 Sep 12;27(37):9901-15.
CAS Number: 1834571-04-8
Molecular Weight: 2632.90
Compound Purity: 99.67
Research Area: Neurological Disease
Solubility: H2O : ≥ 50 mg/mL
Target: iGluR;NO Synthase
Deutsch
English
